田中 智樹 (タナカ トモキ)

Tanaka, Tomoaki

写真a

所属(所属キャンパス)

医学部 放射線科学教室(治療) (信濃町)

職名

助教(有期)

経歴 【 表示 / 非表示

  • 2010年04月
    -
    2012年03月

    慶応義塾大学放射線科学

  • 2012年04月
    -
    2013年03月

    川崎市立川崎病院放射線治療科

  • 2013年04月
    -
    2014年03月

    国立病院機構東京医療センター放射線治療科

  • 2014年04月
    -
    継続中

    慶応義塾大学放射線科学

学歴 【 表示 / 非表示

  • 2008年03月

    岐阜大学, 医学部, 医学科

    大学, 卒業

免許・資格 【 表示 / 非表示

  • 放射線科専門医, 2013年08月

  • 放射線治療専門医, 2016年08月

 

研究分野 【 表示 / 非表示

  • 放射線科学

研究キーワード 【 表示 / 非表示

  • 放射線治療

研究テーマ 【 表示 / 非表示

  • 放射線治療, 

    2014年04月
    -
    継続中

 

論文 【 表示 / 非表示

  • Predictive factors of long-term rectal toxicity following permanent iodine-125 prostate brachytherapy with or without supplemental external beam radiation therapy in 2216 patients

    Tanaka T., Yorozu A., Sutani S., Yagi Y., Nishiyama T., Shiraishi Y., Ohashi T., Hanada T., Saito S., Toya K., Shigematsu N.

    Brachytherapy (Brachytherapy)  17 ( 5 ) 799 - 807 2018年09月

    研究論文(学術雑誌), 共著,  ISSN  15384721

     概要を見る

    © 2018 American Brachytherapy Society Purpose: We analyzed factors associated with rectal toxicity after iodine-125 prostate brachytherapy (BT) with or without external beam radiation therapy (EBRT). Methods and Materials: In total, 2216 prostate cancer patients underwent iodine-125 BT with or without EBRT between 2003 and 2013. The median followup was 6.9 years. Cox proportional hazards modeling was used for univariate and multivariate analyses to assess clinical and dosimetric factors associated with rectal toxicity. Dosimetric parameters from 1 day after implantation (Day 1) and 1 month after implantation (Day 30) were included in the analyses. Results: The 7-year cumulative incidence of Grade 2 or higher rectal toxicity was 5.7% in all patients. The multivariate analysis revealed that antiplatelet or anticoagulant therapy, neoadjuvant androgen deprivation therapy, treatment modality, Day 1 rectal volume receiving 100% of the prescribed dose (RV 100 ), and the Day 30 minimal percent of the prescribed dose delivered to 30% of the rectum (RD 30 ) were associated with rectal toxicity. Day 1 RV 100 was a common predictor in both BT-alone and the BT + EBRT groups. The 5-year cumulative incidence of Grade 2 or higher rectal toxicity was 12.6%, 5.9%, and 1.7% for BT + 3-dimensional conformal radiation therapy, BT + intensity-modulated radiation therapy, and the BT-alone groups, respectively (p < 0.001). Conclusions: Rectal dosimetric parameters in BT were associated with late rectal toxicity. Although the risk of rectal toxicity was higher when EBRT was combined with BT, with proper and achievable rectal dose constraints intensity-modulated radiation therapy yielded less toxicity than 3-dimensional conformal radiation therapy.

  • Prostate-specific antigen nadir within 12 months as an early surrogate marker of biochemical failure and distant metastasis after low-dose-rate brachytherapy or external beam radiotherapy for localized prostate cancer

    Nishimura S., Ohashi T., Momma T., Sakayori M., Eriguchi T., Tanaka T., Yamashita S., Kosaka T., Oya M., Shigematsu N.

    Cancer Medicine (Cancer Medicine)  7 ( 5 ) 1794 - 1801 2018年03月

    研究論文(学術雑誌), 共著

     概要を見る

    © 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. Prostate-specific antigen nadir (nPSA) after radiotherapy for localized prostate cancer has been investigated as a predictor. However, nPSA usually requires several years, limiting its clinical utility. We investigated the significance of nPSA within 12 months (nPSA12) after low-dose-rate prostate brachytherapy (LDR-PB) or external beam radiotherapy (EBRT) on treatment outcomes. Between 2006 and 2014, 663 patients with prostate cancer were treated with LDR-PB or EBRT at two institutions. Four hundred and seventy-four men received LDR-PB and 189 men received EBRT, without androgen deprivation therapy. The Kaplan–Meier method was used for biochemical failure (BF)-free survival (BFFS) and distant metastasis (DM)-free survival (DMFS) analyses, and multivariable Cox regression analysis was performed. The median follow-up was 61.3 months. The median nPSA12 in the LDR-PB and EBRT cohorts was 0.7 and 1.0 ng/mL, respectively. The 7-year BFFS and DMFS rates in LDR-PB patients with nPSA12 ≤ 0.7 ng/mL were 99.1% and 99.5%, respectively; when nPSA12 was >0.7 ng/mL, they were 90.2% and 94.8%, respectively. In EBRT patients with nPSA12 ≤ 1.0 ng/mL, BFFS and DMFS rates were 85.4% and 98.5%, respectively; when nPSA12 was >1.0 ng/mL, they were 67.1% and 87.2%, respectively. nPSA12 was an independent predictor of BF and DM in both cohorts (LDR-PB, P = 0.004 and 0.020, respectively; EBRT, P = 0.005 and 0.041, respectively). The nPSA12 after LDR-PB or EBRT is significantly associated with treatment outcomes of prostate cancer. Higher nPSA12 may identify patients at high risk of relapse who might benefit from salvage treatment.

  • Variability of treatment planning of seed implantation: A Japanese multicenter simulation study.

    Ishiyama H, Nakano M, Toya K, Kota R, Kikuchi K, Yamaguchi T, Kono N, Kawakami S, Tsutsumi Y, Tanaka T, Eriguchi T, Ohga S, Yamaguchi T, Takagawa Y, Morita M, Katayama N, Ohashi T, Aoki M, Yorozu A, Saito S

    Brachytherapy 16 ( 5 ) 1013 - 1020 2017年09月

    研究論文(学術雑誌), 共著

  • Single-energy metal artifact reduction in postimplant computed tomography for I-125 prostate brachytherapy: Impact on seed identification.

    Shiraishi Y, Yamada Y, Tanaka T, Eriguchi T, Nishimura S, Yoshida K, Hanada T, Ohashi T, Shigematsu N, Jinzaki M

    Brachytherapy 15 ( 6 ) 768 - 773 2016年11月

    研究論文(学術雑誌), 共著

  • Permanent prostate brachytherapy with or without supplemental external beam radiotherapy as practiced in Japan: Outcomes of 1300 patients.

    Yorozu A, Kuroiwa N, Takahashi A, Toya K, Saito S, Nishiyama T, Yagi Y, Tanaka T, Shiraishi Y and OhashiT

    Brachytherapy 14 ( 2 ) 111 - 117 2015年03月

    研究論文(学術雑誌), 共著, 査読有り

全件表示 >>

KOARA(リポジトリ)収録論文等 【 表示 / 非表示

研究発表 【 表示 / 非表示

  • 前立腺がん低線量率密封小線源治療後の椎骨静脈叢への線源迷入

    田中 智樹

    日本放射線腫瘍学会第29回学術大会, 2016年10月, ポスター(一般)

  • 前立腺癌に対するIMRT併用小線源療法における直腸毒性の軽減

    田中 智樹

    日本放射線腫瘍学会第26回学術大会, 2013年10月, 口頭(一般)

  • 前立腺癌に対するIMRTの初期経験

    田中 智樹

    第443回日本医学放射線学会関東地方会, 2013年06月, 口頭(一般)

  • 放射線治療中の膵臓の位置に関する検討

    田中 智樹

    第71回日本医学放射線学会総会, 2012年04月, 口頭(一般)

  • ミリプラチンを用いた肝細胞癌に対する肝動脈化学塞栓療法の初期経験

    田中 智樹

    第6回日本IVR学会 関東地方会, 2011年07月, 口頭(一般)

 

担当授業科目 【 表示 / 非表示

  • 放射線医学臨床実習

    2019年度

担当経験のある授業科目 【 表示 / 非表示

  • 放射線医学

    慶應義塾, 2017年度, 通年, 専門科目, 実習・実験, 3時間

    放射線治療計画

  • 放射線科学

    慶應義塾, 2016年度, 通年, 専門科目, 実習・実験, 3時間

  • 放射線医学

    慶應義塾, 2015年度, 通年, 専門科目, 実習・実験, 3時間

  • 放射線科学

    慶應義塾, 2014年度, 通年, 専門科目, 実習・実験, 3時間

  • 放射線科学

    慶應義塾, 2014年度, 通年, 専門科目, 実習・実験, 3時間